Skip to content
KStart free
AI InfrastructureDefenseQuantumAll studies →

A Real-life Study to Understand the Use and Effects of Palbociclib in US Patients With Breast Cancer

← catalyst calendar

NCT06495164 · readout in 133 d

Sponsored by Pfizer (industry) · PFE — their whole pipeline →.

Phase
Status
Active, not recruiting
Study type
Observational
Enrollment
1estimated
Sites
1
Country
United States

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis
DateFiledBasisWhat it is
Start2024-06-24actualWhen the study began enrolling
Primary completion2026-12-30estimatedThe date the last participant is measured for the primary outcome — the readout window
Study completion2026-12-30estimatedThe whole study's end, after follow-up
First posted2024-07-10actualWhen this record first appeared on the registry
Results postedWhen the sponsor posted results to the registry
Record updated2025-11-25actualThe sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Conditions

  • Breast Cancer
  • Malignant Neoplasm of Breast

Interventions

  • Drug: Palbociclib — also filed as Ibrance
  • Drug: Aromatase inhibitor — also filed as a class of drugs included in the study: letrozole (Femara), anastrozole (Arimidex), and exemestane (Aromasin)
  • Drug: Ribociclib — also filed as Kisqali
  • Drug: Abemaciclib — also filed as Verzenio

Primary outcome

what the primary-completion date above is the date OF
Overall Survival (OS)
measured From start of index line of therapy to death, February 2015 - December 2022 or data cutoff

Publications

Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.

Permalink · PFE's whole pipeline · Catalyst calendar · Every registered study · What changed